Table 2 Cox proportional hazards multivariable analysis for overall and progression-free survival outcomes

Cisplatin

 > / = 5 Cycles

Reference

Reference

 < 5 Cycles

2.94

1.58–5.47

 < 0.001

2.32

1.29–4.17

0.005

Gender

 Male

Reference

Reference

 Female

0.76

0.31–1.87

0.55

0.42

0.15–1.18

0.1

Smoker

 Never

Reference

Reference

 Former

1.74

0.76–3.98

0.19

1.89

0.81–4.39

0.14

 Current

1.61

0.58–4.49

0.36

1.38

0.51–3.75

0.53

Age

 < 65

Reference

Reference

 65 or older

0.85

0.46–1.58

0.62

0.73

0.40–1.33

0.3

KPS

 90–100

Reference

Reference

 < 90

1.93

1.02–3.66

0.04

1.91

1.04–3.50

0.04

Race

 White

Reference

Reference

 Other

0.94

0.38–2.33

0.89

1.14

0.48–2.70

0.76

BMI

 Normal

Reference

Reference

 Underweight

0.53

0.12–2.29

0.39

2.9

0.51–16.59

0.23

 Overweight

0.52

0.26–1.05

0.07

0.78

0.39–1.56

0.48

 Obese

0.88

0.38–2.08

0.78

1.13

0.51–2.49

0.77

 Not available

 < 0.001

 < 0.001-Inf

1

 < 0.001

 < 0.001-Inf

1

Site

 Oropharynx

Reference

Reference

 Larynx

0.46

0.19–1.12

0.09

0.6

0.26–1.40

0.24

 Oral cavity

1.91

0.17–21.13

0.6

Jan-84

0.17–20.13

0.62

 Other

1.1

0.49–2.45

0.82

1.06

0.48–2.36

0.89

T staging

 1–2

Reference

Reference

 3–4

2.54

1.30–4.96

0.006

2.71

1.40–5.23

0.003

N staging

 0–1

Reference

Reference

 2–3

1.37

0.58–3.20

0.47

1.46

0.65–3.32

0.36

HPV

 Negative

Reference

Reference

 Positive

0.54

0.20–1.46

0.23

0.76

0.29–1.97

0.57

 Not available

0.92

0.38–2.23

0.86

1.31

0.57–3.03

0.52